Previous Close | 5.40 |
Open | N/A |
Bid | 2.46 |
Ask | 5.30 |
Strike | 81.00 |
Expire Date | 2024-05-17 |
Day's Range | 5.40 - 5.40 |
Contract Range | N/A |
Volume | |
Open Interest | 4 |
WILMINGTON, Del., May 19, 2024--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or smoking status.1 The primary results showed that treatment with AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placeb
The following are the top stories on the business pages of British newspapers. - Anglo American rejected a raised takeover offer of 34 billion pounds ($42.67 billion) from BHP Group on Monday, saying the world's largest listed miner "continues to significantly undervalue" the company. - JPMorgan Chase has pledged a further 40 million pounds ($50.22 million) in philanthropic investments in the UK over five years in a sign of its increasing focus on Britain.
Britain’s two biggest pharmaceutical companies have pledged £430m of investment in France after a charm offensive by Emmanuel Macron.